EPO


Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.

EPO

(Exclusive Provider Organization) See healthcare IT.
References in periodicals archive ?
Graph 2: Distribution and development of Chinese patent applications at the EPO in 2014 by field of technology
2009a) found that, during oxidant injury, EPO directly inhibited such activity, providing protection for the RPE via the PI-3 kinase pathway.
A test to detect the use of EPO in sports was first introduced for the Sydney Olympics in 2000, where Jones won three gold and two bronze medals, and scores of athletes have since been caught and sanctioned.
It remains in the system three times longer than EPO, making it easier to detect once a test is derived.
The new data "provide strong evidence to suggest that EPO is another important factor" in stimulating aberrant vessel growth in diabetic retinopathy, says Lloyd Paul Aiello of Harvard Medical School and the Joslin Diabetes Center in Boston in the same NEJM issue.
No herbal product should be used to excess and EPO can cause headaches and gastrointestinal upset.
Racing Victoria stewards reported EPO to have been found in three vials of Eprex, an artificially produced form of a hormone used in the treatment of cancer.
We ought to pay attention to these kinds of immune responses not only for EPO but for other kinds of gene therapy.
All major IAAF events will also feature tests for EPO, the drug which increases production of red blood cells to convey more oxygen to muscles.
There is nothing but anecdotal evidence concerning the use of EPO in British racing," said their John Maxse.
the key trends (strategic outlook for clinical trials, inclination towards polysialylation and focus on clinical differentiation), industry developments (development of improved biological molecules, ErepoXen Phase IIb intravenous trial underway in India and advent of biosimilars), growth drivers (increasing cases chronic kidney disease (CKD), global dialysis patient population, increasing prevalence of cancer, upcoming patent expiries of original bio drugs, rising adult population worldwide and rising healthcare expenditure) and challenges (risk of thrombosis and PRCA, requirement of extensive clinical trials for obtaining approval, abusive uses of EPO, adverse effects of EPO and escalating price pressure) are also explicated.
The global EPO drugs market is thus driven by increasing number of patients suffering from anemic condition induced due to cancer, HIV and ESRD treatment; favorable reimbursements and increasing commercialization of EPO biosimilars.